.Pharmacolibrary.Drugs.ATC.N.N06AA01

Information

Desipramine is a tricyclic antidepressant (TCA) primarily used to treat major depressive disorder. It acts mainly as a norepinephrine reuptake inhibitor. While it has been largely replaced by newer antidepressants, desipramine is still approved and in use for depression and sometimes off-label for neuropathic pain and attention-deficit hyperactivity disorder (ADHD).

Pharmacokinetics

Population pharmacokinetics in healthy adult volunteers (mixed sex), oral administration.

References

1. Gueorguieva, I, et al., & Chien, JY (2010). Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials. British journal of clinical pharmacology 70(4) 523–536. DOI:10.1111/j.1365-2125.2010.03731.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/20840444

2. Guay, DR (2003). Clinical pharmacokinetics of drugs used to treat urge incontinence. Clinical pharmacokinetics 42(14) 1243–1285. DOI:10.2165/00003088-200342140-00004 PUBMED:https://pubmed.ncbi.nlm.nih.gov/14606931

3. Marasanapalle, VP, et al., & Zack, J (2024). Investigation of the Differences in the Pharmacokinetics of CYP2D6 Substrates, Desipramine, and Dextromethorphan in Healthy African Subjects Carrying the Allelic Variants CYP2D6*17 and CYP2D6*29, When Compared with Normal Metabolizers. Journal of clinical pharmacology 64(5) 578–589. DOI:10.1002/jcph.2366 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37803948

Revisions

• 06/2025 initial generated model